EE81 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab (NIVO+IPI) Versus Pembrolizumab Plus Axitinib (PEM+AXI) for the First-Line Treatment of Intermediate- and Poor (I/P)-Risk Advanced Renal Cell Carcinoma Patients in Colombia

N. Dhanji, G. Van De Wetering, V. Guiot, V. Barco, A. Mejia,J.R. May, J. Garcia, M. Dyer

Value in Health（2023）

Cited 0|Views1

No score

Abstract

Immuno-oncology (IO) combination NIVO+IPI and IO+tyrosine kinase inhibitor combination (PEM+AXI) therapies have demonstrated significant clinical benefits over sunitinib in the first-line (1L) treatment of I/P-risk advanced renal cell carcinoma (aRCC). We examined the cost-effectiveness of NIVO+IPI versus PEM+AXI for this from a Colombian payer perspective, utilizing a novel approach to estimate comparative efficacy between the treatments.

Translated text

Key words

nivolumab plus ipilimumab,versus pembrolizumab,renal cell carcinoma,axitinib,cost-effectiveness,first-line

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined